Journal of the American College of Nutrition, 38 (6), 547551
Timeline of FDA actions on compounded GLP-1 medications The April 30, 2026 proposal is the most significant move yet
Below is a figure from the American Diabetes Association depicting the various actions of GLP-1
DSIP increases neurotransmitter activity, which helps memory, focus, and mental clarity by encouraging relaxation and improved sleep
Interestingly, on undergoing a LOsG/ROS stress, -cells started to re-express fetal nuclear Neurog3 and to dramatically relocate pancreas/duodenum homeobox protein 1 (Pdx1) from the cytoplasm to the nucleus (Fig
These findings challenge the assumption that pharmacologic weight reduction through semaglutide may indirectly improve fertility outcomes [13], and instead raise the possibility of unintended effects when used prior to fertility-related care